OSTEOPOROSIS FRACTURE PREVENTION COST SAVINGS CLAIMS WOULD BE ACCEPTABLE UNDER FDA INTERPRETATION OF PHARMACOECONOMIC CLAIMS LANGUAGE INCLUDED IN S 830
Executive Summary
Cost-effectiveness claims related to tighter control of insulin levels or to fracture prevention would be considered permissible by FDA under its interpretation of the pharmacoeconomic data provisions in the Senate FDA reform bill (S 830).